In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis
Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts...
Gespeichert in:
Veröffentlicht in: | Ophthalmology (Rochester, Minn.) Minn.), 2014-10, Vol.121 (10), p.2059-2065 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2065 |
---|---|
container_issue | 10 |
container_start_page | 2059 |
container_title | Ophthalmology (Rochester, Minn.) |
container_volume | 121 |
creator | Sunada, Atsuko, MT Kimura, Keigo, MT Nishi, Isao, MT, PhD Toyokawa, Masahiro, MT, PhD Ueda, Akiko, MT Sakata, Tomomi, MT Suzuki, Takashi, MD, PhD Inoue, Yoshitsugu, MD, PhD Ohashi, Yuichi, MD, PhD Asari, Seishi, MT, PhD Iwatani, Yoshinori, MD, PhD |
description | Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro. The agents were 1.0% povidone-iodine, 0.05% benzalkonium chloride (BZC), 0.02% chlorhexidine gluconate (CHG), 0.1% propamidine isethionate, 0.02% polyhexamethylene biguanide (PHMB), 5.0% natamycin, and 1.0% voriconazole (VRCZ). These concentrations are those recommended for patients. In addition, 10-fold dilutions of each of the agents were tested. After exposing the cysts to each agent at 35°C for 1 hour or 24 hours, the agents were removed by centrifugal washing. The exposed cysts were observed by optical microscopy for 7 days. In addition, the fine structures of the exposed isolates were examined by transmission electron microscopy (TEM). The genotype of the isolates was determined by 18S rDNA fragment sequencing. Main Outcome Measures The in vitro susceptibility was determined by complete growth inhibition, and the morphologic appearance was determined by TEM. The genotypes of the 56 isolates were determined by 18S rDNA fragment sequencing. Results The Acanthamoeba cysts were most susceptible to natamycin, followed by povidone-iodine, BZC, PHMB, propamidine, and CHG. None of the strains was susceptible to VRCZ. The susceptibilities to PHMB and CHG may be time dependent and to propamidine may be concentration dependent. Transmission electron microscopy showed changes in the inner structure of the cysts exposed to natamycin and povidone-iodine. The Acanthamoeba genotype was T4 in 52 isolates, and cysts with the same genotype had different agent susceptibilities. Conclusions Natamycin and povidone-iodine had excellent cysti-static (or cystcidal) effects, and PHMB and propamidine did not. There was no correlation between agent effectiveness and Acanthamoeba genotype. Therefore, susceptibility tests of isolates are needed to choose the most appropriate agent, and our results can be a guideline for choosing the most appropriate agent for immediate empirical treatment of AK. |
doi_str_mv | 10.1016/j.ophtha.2014.04.013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1566112505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0161642014003601</els_id><sourcerecordid>1566112505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-d736133e4820dcd2c4b051ed54e765a50e80c336fb629a78731e72e3dfc61a0a3</originalsourceid><addsrcrecordid>eNqFkU2OEzEQhS0EYjKBGyDUSzYdqvzXnQ1SNJo_MRILAlvLcVczDp12sN0jzW04CyfDrQws2CCVVJtX71V9xdgbhBUC6vf7VTje53u74oByBaVQPGMLVHJdywbFc7YoMqy15HDGzlPaA4DWQr5kZ1y2LaxBLdj17fjr51efY6guH-ww2ezDmKrQV9tw9M4O1eYbjTlVOVTbSDZXG2fHEnsItLPVR4plIvv0ir3o7ZDo9VNfsi9Xl9uLm_ru0_XtxeaudkqJXHeN0CgEyZZD5zru5A4UUqckNVpZBdSCE0L3O83XtmkbgdRwEl3vNFqwYsnenXyPMfyYKGVz8MnRMNiRwpQMKq0RuQJVpPIkdTGkFKk3x-gPNj4aBDMjNHtzQmhmhAZKld2W7O1TwrQ7UPd36A-zIvhwElC588FTNMl5Gh11PpLLpgv-fwn_GrjBjzPs7_RIaR-mOBaGBk3iBszn-Y3zF1ECCF0cfgNJCph8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1566112505</pqid></control><display><type>article</type><title>In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sunada, Atsuko, MT ; Kimura, Keigo, MT ; Nishi, Isao, MT, PhD ; Toyokawa, Masahiro, MT, PhD ; Ueda, Akiko, MT ; Sakata, Tomomi, MT ; Suzuki, Takashi, MD, PhD ; Inoue, Yoshitsugu, MD, PhD ; Ohashi, Yuichi, MD, PhD ; Asari, Seishi, MT, PhD ; Iwatani, Yoshinori, MD, PhD</creator><creatorcontrib>Sunada, Atsuko, MT ; Kimura, Keigo, MT ; Nishi, Isao, MT, PhD ; Toyokawa, Masahiro, MT, PhD ; Ueda, Akiko, MT ; Sakata, Tomomi, MT ; Suzuki, Takashi, MD, PhD ; Inoue, Yoshitsugu, MD, PhD ; Ohashi, Yuichi, MD, PhD ; Asari, Seishi, MT, PhD ; Iwatani, Yoshinori, MD, PhD</creatorcontrib><description>Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro. The agents were 1.0% povidone-iodine, 0.05% benzalkonium chloride (BZC), 0.02% chlorhexidine gluconate (CHG), 0.1% propamidine isethionate, 0.02% polyhexamethylene biguanide (PHMB), 5.0% natamycin, and 1.0% voriconazole (VRCZ). These concentrations are those recommended for patients. In addition, 10-fold dilutions of each of the agents were tested. After exposing the cysts to each agent at 35°C for 1 hour or 24 hours, the agents were removed by centrifugal washing. The exposed cysts were observed by optical microscopy for 7 days. In addition, the fine structures of the exposed isolates were examined by transmission electron microscopy (TEM). The genotype of the isolates was determined by 18S rDNA fragment sequencing. Main Outcome Measures The in vitro susceptibility was determined by complete growth inhibition, and the morphologic appearance was determined by TEM. The genotypes of the 56 isolates were determined by 18S rDNA fragment sequencing. Results The Acanthamoeba cysts were most susceptible to natamycin, followed by povidone-iodine, BZC, PHMB, propamidine, and CHG. None of the strains was susceptible to VRCZ. The susceptibilities to PHMB and CHG may be time dependent and to propamidine may be concentration dependent. Transmission electron microscopy showed changes in the inner structure of the cysts exposed to natamycin and povidone-iodine. The Acanthamoeba genotype was T4 in 52 isolates, and cysts with the same genotype had different agent susceptibilities. Conclusions Natamycin and povidone-iodine had excellent cysti-static (or cystcidal) effects, and PHMB and propamidine did not. There was no correlation between agent effectiveness and Acanthamoeba genotype. Therefore, susceptibility tests of isolates are needed to choose the most appropriate agent, and our results can be a guideline for choosing the most appropriate agent for immediate empirical treatment of AK.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2014.04.013</identifier><identifier>PMID: 24880905</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acanthamoeba - drug effects ; Acanthamoeba - genetics ; Acanthamoeba - isolation & purification ; Acanthamoeba Keratitis - drug therapy ; Acanthamoeba Keratitis - parasitology ; Anti-Infective Agents, Local - pharmacology ; Antiprotozoal Agents - pharmacology ; Disinfectants - pharmacology ; DNA, Protozoan - analysis ; Genotype ; Humans ; Ophthalmic Solutions - pharmacology ; Ophthalmology ; RNA, Ribosomal, 18S - genetics</subject><ispartof>Ophthalmology (Rochester, Minn.), 2014-10, Vol.121 (10), p.2059-2065</ispartof><rights>American Academy of Ophthalmology</rights><rights>2014 American Academy of Ophthalmology</rights><rights>Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-d736133e4820dcd2c4b051ed54e765a50e80c336fb629a78731e72e3dfc61a0a3</citedby><cites>FETCH-LOGICAL-c553t-d736133e4820dcd2c4b051ed54e765a50e80c336fb629a78731e72e3dfc61a0a3</cites><orcidid>0000-0002-1005-9634</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ophtha.2014.04.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24880905$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sunada, Atsuko, MT</creatorcontrib><creatorcontrib>Kimura, Keigo, MT</creatorcontrib><creatorcontrib>Nishi, Isao, MT, PhD</creatorcontrib><creatorcontrib>Toyokawa, Masahiro, MT, PhD</creatorcontrib><creatorcontrib>Ueda, Akiko, MT</creatorcontrib><creatorcontrib>Sakata, Tomomi, MT</creatorcontrib><creatorcontrib>Suzuki, Takashi, MD, PhD</creatorcontrib><creatorcontrib>Inoue, Yoshitsugu, MD, PhD</creatorcontrib><creatorcontrib>Ohashi, Yuichi, MD, PhD</creatorcontrib><creatorcontrib>Asari, Seishi, MT, PhD</creatorcontrib><creatorcontrib>Iwatani, Yoshinori, MD, PhD</creatorcontrib><title>In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro. The agents were 1.0% povidone-iodine, 0.05% benzalkonium chloride (BZC), 0.02% chlorhexidine gluconate (CHG), 0.1% propamidine isethionate, 0.02% polyhexamethylene biguanide (PHMB), 5.0% natamycin, and 1.0% voriconazole (VRCZ). These concentrations are those recommended for patients. In addition, 10-fold dilutions of each of the agents were tested. After exposing the cysts to each agent at 35°C for 1 hour or 24 hours, the agents were removed by centrifugal washing. The exposed cysts were observed by optical microscopy for 7 days. In addition, the fine structures of the exposed isolates were examined by transmission electron microscopy (TEM). The genotype of the isolates was determined by 18S rDNA fragment sequencing. Main Outcome Measures The in vitro susceptibility was determined by complete growth inhibition, and the morphologic appearance was determined by TEM. The genotypes of the 56 isolates were determined by 18S rDNA fragment sequencing. Results The Acanthamoeba cysts were most susceptible to natamycin, followed by povidone-iodine, BZC, PHMB, propamidine, and CHG. None of the strains was susceptible to VRCZ. The susceptibilities to PHMB and CHG may be time dependent and to propamidine may be concentration dependent. Transmission electron microscopy showed changes in the inner structure of the cysts exposed to natamycin and povidone-iodine. The Acanthamoeba genotype was T4 in 52 isolates, and cysts with the same genotype had different agent susceptibilities. Conclusions Natamycin and povidone-iodine had excellent cysti-static (or cystcidal) effects, and PHMB and propamidine did not. There was no correlation between agent effectiveness and Acanthamoeba genotype. Therefore, susceptibility tests of isolates are needed to choose the most appropriate agent, and our results can be a guideline for choosing the most appropriate agent for immediate empirical treatment of AK.</description><subject>Acanthamoeba - drug effects</subject><subject>Acanthamoeba - genetics</subject><subject>Acanthamoeba - isolation & purification</subject><subject>Acanthamoeba Keratitis - drug therapy</subject><subject>Acanthamoeba Keratitis - parasitology</subject><subject>Anti-Infective Agents, Local - pharmacology</subject><subject>Antiprotozoal Agents - pharmacology</subject><subject>Disinfectants - pharmacology</subject><subject>DNA, Protozoan - analysis</subject><subject>Genotype</subject><subject>Humans</subject><subject>Ophthalmic Solutions - pharmacology</subject><subject>Ophthalmology</subject><subject>RNA, Ribosomal, 18S - genetics</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2OEzEQhS0EYjKBGyDUSzYdqvzXnQ1SNJo_MRILAlvLcVczDp12sN0jzW04CyfDrQws2CCVVJtX71V9xdgbhBUC6vf7VTje53u74oByBaVQPGMLVHJdywbFc7YoMqy15HDGzlPaA4DWQr5kZ1y2LaxBLdj17fjr51efY6guH-ww2ezDmKrQV9tw9M4O1eYbjTlVOVTbSDZXG2fHEnsItLPVR4plIvv0ir3o7ZDo9VNfsi9Xl9uLm_ru0_XtxeaudkqJXHeN0CgEyZZD5zru5A4UUqckNVpZBdSCE0L3O83XtmkbgdRwEl3vNFqwYsnenXyPMfyYKGVz8MnRMNiRwpQMKq0RuQJVpPIkdTGkFKk3x-gPNj4aBDMjNHtzQmhmhAZKld2W7O1TwrQ7UPd36A-zIvhwElC588FTNMl5Gh11PpLLpgv-fwn_GrjBjzPs7_RIaR-mOBaGBk3iBszn-Y3zF1ECCF0cfgNJCph8</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Sunada, Atsuko, MT</creator><creator>Kimura, Keigo, MT</creator><creator>Nishi, Isao, MT, PhD</creator><creator>Toyokawa, Masahiro, MT, PhD</creator><creator>Ueda, Akiko, MT</creator><creator>Sakata, Tomomi, MT</creator><creator>Suzuki, Takashi, MD, PhD</creator><creator>Inoue, Yoshitsugu, MD, PhD</creator><creator>Ohashi, Yuichi, MD, PhD</creator><creator>Asari, Seishi, MT, PhD</creator><creator>Iwatani, Yoshinori, MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1005-9634</orcidid></search><sort><creationdate>20141001</creationdate><title>In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis</title><author>Sunada, Atsuko, MT ; Kimura, Keigo, MT ; Nishi, Isao, MT, PhD ; Toyokawa, Masahiro, MT, PhD ; Ueda, Akiko, MT ; Sakata, Tomomi, MT ; Suzuki, Takashi, MD, PhD ; Inoue, Yoshitsugu, MD, PhD ; Ohashi, Yuichi, MD, PhD ; Asari, Seishi, MT, PhD ; Iwatani, Yoshinori, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-d736133e4820dcd2c4b051ed54e765a50e80c336fb629a78731e72e3dfc61a0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acanthamoeba - drug effects</topic><topic>Acanthamoeba - genetics</topic><topic>Acanthamoeba - isolation & purification</topic><topic>Acanthamoeba Keratitis - drug therapy</topic><topic>Acanthamoeba Keratitis - parasitology</topic><topic>Anti-Infective Agents, Local - pharmacology</topic><topic>Antiprotozoal Agents - pharmacology</topic><topic>Disinfectants - pharmacology</topic><topic>DNA, Protozoan - analysis</topic><topic>Genotype</topic><topic>Humans</topic><topic>Ophthalmic Solutions - pharmacology</topic><topic>Ophthalmology</topic><topic>RNA, Ribosomal, 18S - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sunada, Atsuko, MT</creatorcontrib><creatorcontrib>Kimura, Keigo, MT</creatorcontrib><creatorcontrib>Nishi, Isao, MT, PhD</creatorcontrib><creatorcontrib>Toyokawa, Masahiro, MT, PhD</creatorcontrib><creatorcontrib>Ueda, Akiko, MT</creatorcontrib><creatorcontrib>Sakata, Tomomi, MT</creatorcontrib><creatorcontrib>Suzuki, Takashi, MD, PhD</creatorcontrib><creatorcontrib>Inoue, Yoshitsugu, MD, PhD</creatorcontrib><creatorcontrib>Ohashi, Yuichi, MD, PhD</creatorcontrib><creatorcontrib>Asari, Seishi, MT, PhD</creatorcontrib><creatorcontrib>Iwatani, Yoshinori, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sunada, Atsuko, MT</au><au>Kimura, Keigo, MT</au><au>Nishi, Isao, MT, PhD</au><au>Toyokawa, Masahiro, MT, PhD</au><au>Ueda, Akiko, MT</au><au>Sakata, Tomomi, MT</au><au>Suzuki, Takashi, MD, PhD</au><au>Inoue, Yoshitsugu, MD, PhD</au><au>Ohashi, Yuichi, MD, PhD</au><au>Asari, Seishi, MT, PhD</au><au>Iwatani, Yoshinori, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>121</volume><issue>10</issue><spage>2059</spage><epage>2065</epage><pages>2059-2065</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><abstract>Purpose To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Design Laboratory research. Participants Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. Methods The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro. The agents were 1.0% povidone-iodine, 0.05% benzalkonium chloride (BZC), 0.02% chlorhexidine gluconate (CHG), 0.1% propamidine isethionate, 0.02% polyhexamethylene biguanide (PHMB), 5.0% natamycin, and 1.0% voriconazole (VRCZ). These concentrations are those recommended for patients. In addition, 10-fold dilutions of each of the agents were tested. After exposing the cysts to each agent at 35°C for 1 hour or 24 hours, the agents were removed by centrifugal washing. The exposed cysts were observed by optical microscopy for 7 days. In addition, the fine structures of the exposed isolates were examined by transmission electron microscopy (TEM). The genotype of the isolates was determined by 18S rDNA fragment sequencing. Main Outcome Measures The in vitro susceptibility was determined by complete growth inhibition, and the morphologic appearance was determined by TEM. The genotypes of the 56 isolates were determined by 18S rDNA fragment sequencing. Results The Acanthamoeba cysts were most susceptible to natamycin, followed by povidone-iodine, BZC, PHMB, propamidine, and CHG. None of the strains was susceptible to VRCZ. The susceptibilities to PHMB and CHG may be time dependent and to propamidine may be concentration dependent. Transmission electron microscopy showed changes in the inner structure of the cysts exposed to natamycin and povidone-iodine. The Acanthamoeba genotype was T4 in 52 isolates, and cysts with the same genotype had different agent susceptibilities. Conclusions Natamycin and povidone-iodine had excellent cysti-static (or cystcidal) effects, and PHMB and propamidine did not. There was no correlation between agent effectiveness and Acanthamoeba genotype. Therefore, susceptibility tests of isolates are needed to choose the most appropriate agent, and our results can be a guideline for choosing the most appropriate agent for immediate empirical treatment of AK.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24880905</pmid><doi>10.1016/j.ophtha.2014.04.013</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1005-9634</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0161-6420 |
ispartof | Ophthalmology (Rochester, Minn.), 2014-10, Vol.121 (10), p.2059-2065 |
issn | 0161-6420 1549-4713 |
language | eng |
recordid | cdi_proquest_miscellaneous_1566112505 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Acanthamoeba - drug effects Acanthamoeba - genetics Acanthamoeba - isolation & purification Acanthamoeba Keratitis - drug therapy Acanthamoeba Keratitis - parasitology Anti-Infective Agents, Local - pharmacology Antiprotozoal Agents - pharmacology Disinfectants - pharmacology DNA, Protozoan - analysis Genotype Humans Ophthalmic Solutions - pharmacology Ophthalmology RNA, Ribosomal, 18S - genetics |
title | In Vitro Evaluations of Topical Agents to Treat Acanthamoeba Keratitis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T00%3A50%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%C2%A0Vitro%20Evaluations%20of%20Topical%20Agents%20to%20Treat%20Acanthamoeba%20Keratitis&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Sunada,%20Atsuko,%20MT&rft.date=2014-10-01&rft.volume=121&rft.issue=10&rft.spage=2059&rft.epage=2065&rft.pages=2059-2065&rft.issn=0161-6420&rft.eissn=1549-4713&rft_id=info:doi/10.1016/j.ophtha.2014.04.013&rft_dat=%3Cproquest_cross%3E1566112505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1566112505&rft_id=info:pmid/24880905&rft_els_id=1_s2_0_S0161642014003601&rfr_iscdi=true |